Hypothalamic releasing factors and Parkinson disease.
Hypothalamic releasing factors and Parkinson disease.
复制标题
下丘脑释放因子与帕金森病。
作者：
T. Chase;A. C. Woods;M. Lipton;C. E. Morris
对特发性帕金森综合征患者进行促甲状腺激素释放激素或黑素细胞刺激素释放抑制因子静脉滴注治疗试验。促甲状腺激素释放激素对5名未经治疗的患者的锥体外系功能没有一致的影响，也没有显著改变其他6名患者对左旋多巴的反应。在6名未经治疗的患者中，有3名患者的黑素细胞刺激素释放抑制因子起到了轻微的改善作用，而在5名接受左旋多巴治疗的患者中，有2名患者的抗帕金森症疗效增强，3名患者的运动障碍症状增加。然而，在两组中，这些影响都没有达到统计学意义。
Therapeutic trials of intravenously infused thyrotrophin-releasing hormone or melanocyte-stimulating hormone releaseinhibiting factor were conducted in patients with idiopathic parkinsonism. Thyrotrophin-releasing hormone had no consistent effect on extrapyramidal function in five otherwise untreated patients, nor did it significantly modify the response to levodopa in six other individuals. Melanocyte-stimulating hormone release-inhibiting factor exerted a mild amelioratory effect in three of six untreated patients, while in five levodopatreated individuals antiparkinsonian efficacy was potentiated in two and dyskinesias increased in three. In neither group, however, did these effects attain statistical significance.